Research report
Degeneration of speech, language, and hearing in a patient with mucopolysaccharidosis VII

https://doi.org/10.1016/0165-5876(90)90215-DGet rights and content

Abstract

Mucopolysaccharidosis VII (MPS-VII) is probably the rarest of the mucopolysac-charidoses; literature reveals only 20 cases. We have had the opportunity to study and treat such a child in our clinic, and this paper documents his speech, language, and hearing. Results demonstrated a delay with respect to his chronological age in all cognitive, linguistic, and social domains. He had a mixed hearing loss which could have contributed to his diminishing speech and language abilities; he had chronic otitis media. After 59 h of speech and language intervention (over a period of 19 months), primarily for language treatment, standardized tests revealed that his scores had decreased over time. During this period, both his speech production and his hearing got poorer. At about the time of his 8th birthday, he underwent a permanent tracheostomy, altering further therapy. Although MPS-VII is a very rare disorder, what has been learned here may apply to other MPSs and even to other multiply handicapped patients. We hope that the presentation of our findings may assist others when confronted with complex, degenerative disorders.

References (19)

There are more references available in the full text version of this article.

Cited by (20)

  • Neuropsychology assessment and outcomes in adult mucopolysaccharidosis – A systematic review as the first step to service development in a large tertiary Lysosomal Storage Disorders centre

    2023, Molecular Genetics and Metabolism
    Citation Excerpt :

    Yet adults with MPS have received limited attention in the literature, and hence little guidance exists on the clinical management of cognitive and psychological difficulties faced by these patients and their families. MPS I, II, III and VII involve progressive central nervous system (CNS) disease, causing cognitive impairment, behavioural abnormalities, sleep problems and/or seizures [3–9], psychosis, anxiety, depression, and autistic spectrum disorder [3,10]. Neuropsychological abnormalities and mental health problems have also been found in attenuated forms of MPS I, II, III [11], MPS IV and in MPS VI [12–15], and in some cases may still manifest significant cognitive impairments [16].

  • Epilepsy in mucopolysaccharidosis disorders

    2017, Molecular Genetics and Metabolism
  • Practical management of behavioral problems in mucopolysaccharidoses disorders

    2017, Molecular Genetics and Metabolism
    Citation Excerpt :

    During this meeting, 39 experts reviewed and discussed existing relevant literature and clinical data on the management of behavioral problems in MPS disorders. MPS VII was not discussed during this meeting due to its extreme rarity [12] and will therefore not be the focus of this review. Relevant literature was further obtained from PubMed searches for “Child Behavior Disorders/therapy”[MeSH] AND “Mucopolysaccharidoses”[MeSH] (5 items), “Mental Disorders/therapy”[MeSH] AND “Mucopolysaccharidoses”[MeSH] (32 items), and “Mucopolysaccharidoses”[MeSH] AND “Behavior”[MeSH] (112 items).

  • Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses

    2017, Molecular Genetics and Metabolism
    Citation Excerpt :

    In addition to a variety of somatic clinical manifestations that vary considerably between and within MPS types, patients with rapidly progressing/severe MPS I (Hurler [IH]), II (neuronopathic type), III, and VII (all associated with accumulation of heparan sulfate) show involvement of the central nervous system (CNS) [1,3,4]. CNS indicators include cognitive impairment in the forms of MPS mentioned above, and behavioral abnormalities, sleep problems, and/or seizures in select forms [1,4–11]. Because of the debilitating nature of cognitive impairment in MPS patients, and the substantial impact on the lives of both the patients and their families, it is considered a relevant symptom for improvement when developing therapies.

View all citing articles on Scopus

Presented at the annual meeting of the Society for Ear, Nose and Throat Advances in Children, New York, December 1988.

Deceased December 1989.

View full text